WITHDRAWN: FDA grants accelerated approval to melphalan flufenamide for relapsed or refractory multiple myeloma

FDA announced its final decision to withdraw approval of melphalan flufenamide (Pepaxto) with dexamethasone to treat certain patients with multiple myeloma.

Source: FDA Center for Drug Evaluation and Research - What's New - February 23, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news